The advanced HeliTrax^SM System is wireless, mobile technology designed to strengthen the connection between you and your treatment center. This one-of-a-kind data management system enables you and your treatment center team to improve the overall management of your bleeding disorder.

In addition to the benefits of proven efficacy and safety^1–4, patients on Helixate^® FS can now have a friendlier experience managing their therapy with the new HeliTrax^SM System.

You and your treatment center team stay in touch

• Wireless, Internet-based electronic diary and web interface makes data entry easy and offers you the peace of mind that comes with a dependable connection to your HTC team
• Data compiled in one report for a clear, clinical snapshot of you

Treatment stays on track

• Access to your data before and between visits enables your HTC team to address any complications or concerns you may have with treatment
• Emergency bleeding events can be rapidly assessed with high-priority messaging and picture-taking capabilities

Improved care with a comprehensive view of your clinical picture

• Continuous tracking of medication usage, inventory, bleeding events, and follow-up—all graphically displayed in one report
• Clinical assessment—before and between visits
• Rapid assessment of bleeding events anywhere and at any time with built-in camera feature
– Send a high-priority message directly to your treatment center in emergency bleeding event situations
– Describes in detail the specifics of a bleeding event, complete with location, symptoms, and picture

Closer to the data management needs of your treatment center

• Reduces the chance of documentation and transcription errors
• Saves time by eliminating paperwork and directing only high-priority messages to your HTC staff’s attention
• Provides a JCAHO-compliant progress report for your medical records

For more information about the HeliTrax^SM System, please call CSL Behring Consumer Affairs at 1-888-508-6978.

1. 1. Kreuz W, Gill JC, Rothschild C, et al, and the International Kogenate-FS Study Group. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost. 2005;93:457–467.
2. 2. Oldenburg J, Ivaskevicius V, Schröder J, Müller CR, Ganguly A. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII. Thromb Haemost. 2006;95:903–905.
3. 3. Abshire TC, Brackmann H-H,Scharrer I, et al, and the International Kogenate-FS Study Group. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy: results of a multicenter, international, clinical investigation. Thromb Haemost. 2000;83:811–816.
4. 4. Data on file, Bayer Corporation.